Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Clinical evidence

APC-003

30 evidence topics · 3 sources

Objective
Location and study date
Registered study dates
FieldQuoted record
Study start (actual)“2020-10-27”
Primary completion (actual)“2021-05-28”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using hypoxic burden as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled and analyzed participants in the registry
Description of analysis sets
Results
Participant disposition
Participants starting and completing each period, with reasons for not completing
Baseline characteristics
Efficacy results
Registry primary outcome: least squares mean change in log10 hypoxic burden (95% confidence interval), events with 4% or greater desaturation, mITT
TreatmentLog10HB4%[%min/hour]
AD109 (n = 59)“-0.41 (-0.54 to -0.28)”
Atomoxetine (n = 59)“-0.36 (-0.49 to -0.23)”
R-oxybutynin (n = 59)“-0.04 (-0.17 to 0.09)”
Placebo (n = 59)“-0.06 (-0.18 to 0.07)”
Health-related quality of life and patient-reported outcomes
Safety results
Registry adverse events: deaths, serious adverse events, and other adverse events at a 3% threshold
EventA: AD109B: Atomoxetine 75 mg + placeboC: R-oxybutynin 2.5 mg + placeboD: Placebo + placebo
All-cause mortality“0/56 (0.00%)”“0/54 (0.00%)”“0/54 (0.00%)”“0/57 (0.00%)”
Serious adverse events, total“1/56 (1.79%)”“0/54 (0.00%)”“0/54 (0.00%)”“0/57 (0.00%)”
Atrial fibrillation (serious)“1/56 (1.79%)”“0/54 (0.00%)”“0/54 (0.00%)”“0/57 (0.00%)”
Seizure (serious)“1/56 (1.79%)”“0/54 (0.00%)”“0/54 (0.00%)”“0/57 (0.00%)”
Gastroesophageal reflux disease“2/56 (3.57%)”“2/54 (3.70%)”“0/54 (0.00%)”“0/57 (0.00%)”
Study limitations
Summary
  • Publication status: results are available only from the registry record and the company prospectus.
  • Design: four-period single-dose crossover with one-week washouts; participants who withdrew were not replaced, and 49 participants started the fourth period. The registry states the analysis did not analyze data by period and reported adverse events by treatment group only.
  • Eligibility differs by source: the registry states AHI 10 to below 20, or 20 or more if other polysomnography criteria were met, while the prospectus states AHI 10 to 45 events/h with randomization limited to participants showing signs of low upper airway collapsibility. Ages were 25 to 65, and exclusions included a history of insomnia and clinically significant cardiac disease.
  • Open-label extension: 37 of 60 participants received AD109 for 4 weeks without a control group; the reported reductions in hypoxic burden and AHI at week 4 and the SAQLI change versus baseline come from the prospectus.
  • Withdrawals differ by source: the registry lists first-period non-completion as incorrectly randomized, lost to follow-up, and physician decision (1 each), while the prospectus states two participants withdrew because of adverse events (pleurisy and atrial fibrillation).
  • Safety: one serious adverse event (possible seizure versus arrhythmia or atrial fibrillation) occurred with AD109 in a participant with a previously undisclosed history of arrhythmia and was considered unrelated to the drug.
  • Sponsor: the prospectus describes APC-003 as a trial the company initiated.